Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer
Open accessAbstract
OBJECTIVE: The objective of the present study was to evaluate the incidence, time of onset, and extent of hemoglobin, testosterone, and erythropoietin changes in patients with localized prostate cancer receiving either radiation alone or radiation combined with total androgen blockade (tab). METHODS: The study enrolled 35 patients (median age: 69 years) with clinically localized prostate cancer who received 3-dimensional conformal radiation with or without tab. Patients were generally treated with radiation alone (group 1), radiation plus short-term (≤6 months) tab (group 2), or radiation plus long-term (≥2 years) tab (group 3). Serum hemoglobin, testosterone, and erythropoietin in these patients were prospectively evaluated. RESULTS: The mean baseline serum hemoglobin for group 1 (n = 20), group 2 (n = 6), and group 3 (n = 9) was 149 g/L, 153 g/L, and 143 g/L respectively. We observed no significant decline in serum hemoglobin, testosterone, or erythropoietin among patients treated with radiotherapy alone. A significant drop in serum testosterone was noted in the group 2 and 3 patients within 1 month (p < 0.001), reaching a plateau at approximately 6 months. That change was followed by a significant decline (p < 0.001) in serum hemoglobin at 3-6 months (137 g/L in group 2 and 129 g/L in group 3). We observed a small but statistically significant increase in serum erythropoietin (p < 0.001) of 8 U/L in group 2 and 4 U/L in group 3 after 6 months of tab. No immediate recovery in serum hemoglobin, testosterone, or erythropoietin was observed upon completion of tab. CONCLUSIONS: Although conformal radiotherapy alone for localized prostate cancer had no effect on serum hemoglobin, testosterone, or erythropoietin, tab led to a significant decline in testosterone, which was followed by decline in hemoglobin that was not a result of a deficiency of erythropoietin.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Circulating hemoglobin shows a progressive fall for 6 months reaching a nadir and plateau at 12 to 16 months in six studies involving 534 men undergoing medical castration for prostate cancer.
“For example, circulating hemoglobin shows a progressive fall for 6 months reaching a nadir and plateau at 12 to 16 months in six studies involving 534 men undergoing medical castration for prostate cancer (179–184).”
From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., van Tienhoven, G., van den Bergh, A. C. M., Oddens, J. R., Poortmans, P. M., Gez, E., Kil, P. J. M., Akdaş, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970 · see citing works
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D. L., McGowan, D. G., Amin, M. B., CHETNER, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M. Z., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696 · see citing works
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622 · see citing works
D'Amico, A. V., Moul, J. W., Carroll, P. R., Sun, L. L., Lubeck, D. P., & Chen, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.075 · Cited by 453 · see citing works
Pommier, P., Chabaud, S., Lagrange, J., Richaud, P. M., Lesaunier, F., Prisé, É. L., Wagner, J. P., Hay, M. H., Beckendorf, V., Suchaud, J.-P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5171 · Cited by 340 · see citing works
Androgen deprivation therapy in the treatment of advanced prostate cancer.
Perlmutter, M. A., & Lepor, H. (2007) · PubMed · Cited by 288 · see citing works
STRUM, S. B., McDERMED, J. E., SCHOLZ, M. C., JOHNSON, H., & TISMAN, G. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00234.x · Cited by 215 · see citing works
Labrie, F., Dupont, A., Bèlanger, A., Giguère, M., Lacoursiere, Y., Emond, J., Monfette, G., & Bergeron, V. (1985) · Journal of Steroid Biochemistry · doi:10.1016/s0022-4731(85)80024-8 · Cited by 152 · see citing works
Hamilton, J. B. (1948) · Elsevier eBooks · doi:10.1016/b978-1-4831-9891-0.50013-0 · Cited by 103 · see citing works
Saylor, P. J., & Smith, M. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0014 · Cited by 100 · see citing works
Leuprolide With and Without Flutamide in Advanced Prostate Cancer
Crawford, E. D., Blumenstein, B. A., Goodman, P. J., Davis, M. A., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R. C., & Dorr, F. A. (1990) · Cancer · doi:10.1002/cncr.1990.66.s5.1039 · Cited by 84 · see citing works
Weber, J. P., Walsh, P. C., Peters, C. A., & Spivak, J. L. (1991) · American Journal of Hematology · doi:10.1002/ajh.2830360306 · Cited by 76 · see citing works
Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment
Akaza, H. (2010) · Pharmacology · doi:10.1159/000274486 · Cited by 42 · see citing works
Beer, T. M., Tangen, C. M., Bland, L. B., Hussain, M., Goldman, B. H., DeLoughery, T. G., & Crawford, E. D. (2006) · Cancer · doi:10.1002/cncr.22029 · Cited by 40 · see citing works
Eri, L. M., & Tveter, K. J. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32760-x · Cited by 35 · see citing works
Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer
Ornstein, D. K., Beiser, J. A., & Andriole, G. L. (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00844.x · Cited by 34 · see citing works
Curtis, K. K., Adam, T. J., Chen, S., Pruthi, R. K., & Gornet, M. K. (2008) · The Aging Male · doi:10.1080/13685530802172438 · Cited by 23 · see citing works
A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient
TOMBAL, B. F. (2009) · Urologia Internationalis · doi:10.1159/000251174 · Cited by 22 · see citing works
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Lawton, C. A. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.05.028 · Cited by 14 · see citing works
Cancer de la prostate et hormonothérapie : indications thérapeutiques de première ligne
BOCCON-GIBOD, L., Richaud, P. M., Coloby, P. J., Coulange, C., Culine, S., Davin, J., Soulie, M., & Zerbib, M. (2009) · The French Journal of Urology · doi:10.1016/j.purol.2009.11.001 · Cited by 6 · see citing works
[Anaemia and prostatic cancer].
Boustany, R., & Zerbib, M. (2005) · PubMed · Cited by 2 · see citing works
Asbell (1996) · doi:10.1002/(sici)1097-0045(199610)29:4
Flagged first, then by citations
Research works printed but not linked: 2
- Boccon-Gibod L, Richaud P, Coloby P, et al. First-line indica- tions for hormonal therapy in prostate cancer [French]. Prog Urol 2010;20:109-15.
- Copyright © 2012 Multimed Inc. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC). among men with prostate cancer. J Natl Compr Canc Netw 2010;8:211-23.
Cited by
Sorted by citations
Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance
Handelsman, D. J., Hirschberg, A. L., & Bermon, S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00020 · Cited by 594 · see citing works
Farhood, B., Mortezaee, K., Haghi‐Aminjan, H., Khanlarkhani, N., Salehi, E., Nashtaei, M. S., Najafi, M., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28283 · Cited by 50 · see citing works
Maggio, M. G., Vita, F. D., Fisichella, A., Lauretani, F., Ticinesi, A., Ceresini, G., Cappola, A. R., Ferrucci, L., & Ceda, G. P. (2015) · International Journal of Endocrinology · doi:10.1155/2015/292574 · Cited by 44 · see citing works
Gonzales, G. F. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2012.170 · Cited by 32 · see citing works
Gonzales, G. F., & Chaupis-Meza, D. (2014) · Andrologia · doi:10.1111/and.12359 · Cited by 23 · see citing works
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer
Numakura, K., Kobayashi, M., Muto, Y., Sato, H., Sekine, Y., Sobu, R., Aoyama, Y., Takahashi, Y., Okada, S., Sasagawa, H., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090587 · Cited by 24 · see citing works
Vargas, A., Machado, R. D., Filho, D. I., Paiva, C. E., dos Reis, R. B., Tobias‐Machado, M., & Faria, E. F. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1831-5 · Cited by 14 · see citing works
Zhang, C., Zhongxing, L., Qiang, C., Chao, Q., Hongzhou, C., Hai, Z., Qian, J., Tao, L., Ju, X., & Chang-jun, Y. (2014) · Journal of Biomedical Research · doi:10.7555/jbr.28.20130126 · Cited by 9 · see citing works
Mortezaee, K., Motallebzadeh, E., Milajerdi, A., Farhood, B., Najafi, M., & Sahebkar, A. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200128112558 · Cited by 7 · see citing works
Efectos de la suplementación con testosterona sobre el rendimiento en resistencia
Fernández-Díaz, P., & Domínguez, R. (2016) · Revista Andaluza de Medicina del Deporte · doi:10.1016/j.ramd.2015.02.011 · Cited by 3 · see citing works
Ebbinge, M., Berglund, A., Varenhorst, E., Hedlund, P. O., Sandblom, G., & the Scandinavian Prostate Cancer Group (SPCG)‐5 Study Group (2018) · British Journal of Urology · doi:10.1111/bju.14227 · Cited by 2 · see citing works
- Authors
- Golfam, M., Samant, R., Eapen, L., & Malone, S.
- Affiliations
- Ottawa Hospital (CA)
- Corresponding author
- Golfam, M.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2012-08-01
- Volume
- 19
- Issue
- 4
- Pages
- 258-263
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- PMC
- PMC3410837
- OpenAlex
- W2151990340
- Cited by
- 11
- References
- 22
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Current Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Ottawa
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- localized prostate cancer, total androgen blockade, radiotherapy, serum hemoglobin, testosterone, erythropoietin, anemia, 3D conformal radiotherapy, androgen deprivation therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
